BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 15337540)

  • 1. Clinical radiobiology of stage T2-T3 bladder cancer.
    Majewski W; Maciejewski B; Majewski S; Suwinski R; Miszczyk L; Tarnawski R
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):60-70. PubMed ID: 15337540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why to start the concomitant boost in accelerated radiotherapy for advanced laryngeal cancer in week 3.
    Terhaard CH; Kal HB; Hordijk GJ
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):62-9. PubMed ID: 15850903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised trial of accelerated radiotherapy for localised invasive bladder cancer.
    Horwich A; Dearnaley D; Huddart R; Graham J; Bessell E; Mason M; Bliss J
    Radiother Oncol; 2005 Apr; 75(1):34-43. PubMed ID: 15878099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced head and neck carcinoma in women: treatment outcomes may not improve with accelerated hyperfractionated radiotherapy.
    Leborgne F; Leborgne JH; Fowler JF; Zubizarreta E; Mezzera J
    Cancer; 2001 Jun; 91(12):2353-60. PubMed ID: 11413525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of overall treatment time and radiobiological parameters on biologically effective doses in cervical cancer patients treated with radiation therapy alone.
    Gasinska A; Fowler JF; Lind BK; Urbanski K
    Acta Oncol; 2004; 43(7):657-66. PubMed ID: 15545186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Results of long-term treatment of inoperable cancer of the bladder with cisplatin and concurrent irradiation: prognostic factors of local control and survival].
    Chauvet B; Félix-Faure C; Davin JL; Choquenet C; Alfonsi M; Reboul F
    Cancer Radiother; 1998 Apr; 2 Suppl 1():85s-91s. PubMed ID: 9749086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility and early results of accelerated radiotherapy for head and neck carcinoma in the elderly.
    Allal AS; Maire D; Becker M; Dulguerov P
    Cancer; 2000 Feb; 88(3):648-52. PubMed ID: 10649260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy.
    Zhang Z; Liao Z; Jin J; Ajani J; Chang JY; Jeter M; Guerrero T; Stevens CW; Swisher S; Ho L; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):656-64. PubMed ID: 15708243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: a study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG).
    Teo PM; Leung SF; Tung SY; Zee B; Sham JS; Lee AW; Lau WH; Kwan WH; Leung TW; Chua D; Sze WM; Au JS; Yu KH; O SK; Kwong D; Yau TK; Law SC; Sze WK; Au G; Chan AT
    Radiother Oncol; 2006 Apr; 79(1):27-33. PubMed ID: 16626829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerated hyperfractionated radiotherapy for cervical cancer: multi-institutional prospective study of forum for nuclear cooperation in Asia among eight Asian countries.
    Ohno T; Nakano T; Kato S; Koo CC; Chansilpa Y; Pattaranutaporn P; Calaguas MJ; de Los Reyes RH; Zhou B; Zhou J; Susworo R; Supriana N; Dung TA; Ismail F; Sato S; Suto H; Kutsutani-Nakamura Y; Tsujii H
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1522-9. PubMed ID: 17919839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer.
    Koukourakis MI; Tsolos C; Touloupidis S
    Urology; 2007 Feb; 69(2):245-50. PubMed ID: 17320657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organ-sparing treatment in muscle-invasive bladder cancer.
    Dunst J; Diestelhorst A; Kühn R; Müller AC; Scholz HJ; Fornara P
    Strahlenther Onkol; 2005 Oct; 181(10):632-7. PubMed ID: 16220401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcome and prognostic variables for local control and survival in patients receiving radical radiotherapy for urinary bladder cancer.
    Fokdal L; Høyer M; von der Maase H
    Acta Oncol; 2004; 43(8):749-57. PubMed ID: 15764221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute and late toxicity in radical radiotherapy for bladder cancer.
    Majewski W; Tarnawski R
    Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):598-609. PubMed ID: 19632819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.